MaxCyte (NASDAQ:MXCT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of MaxCyte (NASDAQ:MXCT) from a sell rating to a hold rating in a report issued on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, MaxCyte has an average rating of “Hold” and a consensus price target of $7.00.

MaxCyte Trading Down 2.1%

Shares of MXCT stock opened at $0.79 on Friday. The firm has a market capitalization of $84.42 million, a P/E ratio of -1.80 and a beta of 1.21. MaxCyte has a 1 year low of $0.75 and a 1 year high of $4.42. The firm’s fifty day simple moving average is $1.35 and its 200 day simple moving average is $1.51.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The company had revenue of $6.41 million during the quarter, compared to analyst estimates of $8.37 million. MaxCyte had a negative return on equity of 23.50% and a negative net margin of 132.57%. Equities research analysts anticipate that MaxCyte will post -0.42 EPS for the current fiscal year.

Hedge Funds Weigh In On MaxCyte

A number of hedge funds have recently modified their holdings of MXCT. Nano Cap New Millennium Growth Fund L P acquired a new stake in MaxCyte in the 4th quarter valued at $356,000. Cabot Wealth Management Inc. bought a new position in shares of MaxCyte during the fourth quarter valued at $137,000. SG Americas Securities LLC boosted its stake in shares of MaxCyte by 98.1% in the 4th quarter. SG Americas Securities LLC now owns 49,402 shares of the company’s stock valued at $77,000 after purchasing an additional 24,467 shares in the last quarter. Mirabella Financial Services LLP grew its holdings in shares of MaxCyte by 24.2% in the 3rd quarter. Mirabella Financial Services LLP now owns 8,200,000 shares of the company’s stock worth $12,956,000 after purchasing an additional 1,600,000 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of MaxCyte by 122.8% in the 3rd quarter. XTX Topco Ltd now owns 389,071 shares of the company’s stock worth $615,000 after purchasing an additional 214,405 shares during the last quarter. 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.